TYK MEDICINES-B Shares Surge Over 5% Following H-Share Reform Completion and New Drug Application Milestone

DanNuo Pharma's IPO: R&D Cuts, 3-Year Loss of 376 Million Yuan, and Hidden Risks in Commercial Partnership

Voices from China's Pharmaceutical Sector at the 2026 "Two Sessions"

Proposals from Deputies and Committee Members on Enhancing Centralized Drug Procurement and Deepening Medical Insurance Payment Reforms

34-Year-Old Female Leader from Chaoshan Secures Major $1.5 Billion Pharmaceutical Deal

Senior Pharmaceutical Analyst Leaves High-Paying Career to Pursue Buddhist Studies

TYK MEDICINES-B Completes H-Share Full Circulation Process

Senior Pharmaceutical Analyst Pursues Buddhist Studies Master's Degree: What's Your Take?

ABBISKO-B Initiates First Patient Dosing in Phase I/II Trial for Oral KRAS G12D Inhibitor ABSK141

Tigermed Finalizes Divestiture of Shanghai Guanhe Medical's Entire Equity

FRONTAGE Subsidiary Finalizes Acquisition of Shanghai Guanhe Medical Technology

Medical Device Stocks Emerge as Top Pick for Year of the Horse, Led by Aidite's 105% Surge

GENFLEET-B's GFH375 Receives Breakthrough Therapy Designation in China for KRAS G12D-Mutant NSCLC

DanNuo Pharma's Commercialization Challenge: R&D Spending Declines, Nearly 800 Million Yuan Partnership Hides Performance Clauses

HENLIUS's Biosimilar HLX11 Receives Positive CHMP Review from EMA

TYK MEDICINES-B Announces RMB 83.5 Million Capital Injection into Subsidiary

Pharmaceutical Industry Update: Key Developments on February 27

Yixintang to Capitalize on Market Opportunities and Expand Business Boundaries for Healthcare-Consumer Integration

Zhongtai Securities: Maintaining Focus on Healthcare's Structural Opportunities and Medical AI+

Waterdrop's Yifan Pharma Deploys China's First AI-Powered Patient Matching Patent for Clinical Trials